Substance Abuse & Awareness Workshop hosted in Fayette County
In addition to presenting pertinent information on detection and prevention of substance abuse in younger members of the community, the event featured guest speaker Jermaine Galloway, an internationally recognized authority on drug and alcohol prevention and education.
A former law enforcement officer, Galloway has taken his message of prevention across the nation and beyond through his nonprofit organization, Tall Cop Says Stop. During Tuesday's workshop presentation, Galloway noted that while Fentanyl remains a vital threat, community members should also be aware of more accessible substances finding their way into the hands of community youth.'He made the point that there is a lot of focus on the Fentanyl crisis because there is death and destruction right in front of us,' said Community Connections Partnership for Success Coordinator, Heather Green of the presentation. 'However, there is a whole fire behind us and that would be referring to those other substances.'
Drug-Free Communities Program Director, Suzanne Wood stressed the importance of prevention early on as a means of circumventing issues later in life.'It's important because 90% of addiction begins in the teen years,' said Wood. 'The more we can prevent drug use from starting, the less we have to spend in the treatment of that drug – whether it is monetary or time.'
Drug-Free Communities Project Coordinator, Amanda Withrow tells 59News that the workshop drew attendance from individuals from a variety of backgrounds, all of whom were united in a collective hope to gain further insight on the substance abuse epidemic impacting the region.'We also had people from different sectors: the schools – the Board of Education, for instance – law enforcement, health departments, parents, teachers, and government officials. So it was a great turnout. We're really pleased,' said Withrow.
Those concerned with substance abuse among the youth at the local level are encouraged to get involved and to utilize resources made available by local organizations like the Fayette Prevention Coalition.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
43 minutes ago
- Yahoo
Eli Lilly raises UK price of obesity drug by up to 170% after Trump ‘freeloading' gripe
Eli Lilly has raised the UK price of its popular weight-loss drug Mounjaro by as much as 170 per cent, as it tries to address complaints by Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
8 hours ago
- Yahoo
Drug that slows onset of type 1 diabetes licensed for use in UK-first
A groundbreaking drug that slows down the development of type 1 diabetes has been licensed for use in the UK. Teplizumab can allow patients to live 'normal lives' without the need for insulin injections. Experts hailed the decision by the Medicines and Healthcare Regulatory Agency (MHRA) as a 'breakthrough moment' that represents a 'turning point' in how the condition is treated. About 400,000 people in the UK have type 1 diabetes, a lifelong condition which causes the immune system to attack insulin-producing cells in the pancreas. Insulin helps the body use sugar for energy, and without this hormone, blood sugar levels can become dangerously high. Type 1 diabetes needs constant management to keep blood sugar within range, with patients required to take insulin through injections or pumps. Teplizumab trains the immune system to stop attacking pancreatic cells. It is taken by an IV drip for a minimum of 30 minutes over 14 consecutive days. The drug, which is already approved in the US, has been authorised for use by the MHRA to delay the onset of stage three type 1 diabetes in adults and children aged eight or over by an average of three years. Ahmed Moussa, general manager of general medicines UK and Ireland at Sanofi, which makes teplizumab, said: 'One hundred years ago the discovery of insulin revolutionised diabetes care. Today's news marks a big step forward.' The UK is the first country in Europe to be granted a licence. Type 1 diabetes develops gradually in three stages over months or years. Stage three is usually when people start to experience blood sugar problems and are diagnosed with the condition. According to the MHRA, teplizumab is used in people with stage two type 1 diabetes, which is an earlier stage of the disease during which patients are at a high risk of progressing to stage three. Parth Narendran, a professor of diabetes medicine at the University of Birmingham and The Queen Elizabeth Hospital Birmingham, said: 'Teplizumab essentially trains the immune system to stop attacking the beta cells in the pancreas, allowing the pancreas to produce insulin without interference. 'This can allow eligible patients to live normal lives, delaying the need for insulin injections and the full weight of the disease's daily management by up to three years. It allows people to prepare for disease progression rather than facing an abrupt emergency presentation.' Following the decision by the MHRA, the cost-effectiveness of teplizumab will be assessed by NHS spending watchdog the National Institute for Health and Care Excellence (Nice) to determine if it can be rolled out on the health service. Karen Addington, chief executive of the charity Breakthrough T1D, said: 'I am personally delighted and welcome the MHRA's approval of teplizumab. 'After years of research, clinical trials and drug development, we have an incredible breakthrough.' Reacting to the announcement, Dr Elizabeth Robertson, director of research and clinical at Diabetes UK, said: 'Today's landmark licensing of teplizumab in the UK marks a turning point in the treatment of type 1 diabetes. 'For the first time, we have a medicine that targets the root cause of the condition, offering three precious extra years free from the relentless demands of managing type 1 diabetes.' Dr Robertson added that the 'next steps are critical'. 'To ensure teplizumab reaches everyone who could benefit, we need it to be made available on the NHS, and the rollout of a screening programme to identify those with early-stage type 1 diabetes,' she said.
Medscape
12 hours ago
- Medscape
Teen Suicide, Binge Drinking Decline, New National Data Show
The use of cocaine, alcohol, and prescription opioids in the US has declined over the last 4 years, data from the 2024 National Survey on Drug Use and Health showed. Among adolescents aged 12-17 years, suicidal ideation and attempts declined. Nearly 1 in 5 reported moderate or severe symptoms of generalized anxiety disorder. This is the first time this outcome has been included in the survey. The percentage of those aged 12 years or above with a drug use disorder in the past year increased from 8.7% in 2021 to 9.8% in 2024 whereas those with a past-year alcohol use disorder decreased from 10.6% to 9.7% over the same time period. The data consist of self-reported surveys from nearly 70,000 people aged 12 years or above across the country and details trends of mental health conditions and substance use change. 'These data are incredibly valuable to researchers, clinicians, policymakers, and others, allowing for greater understanding of the nation's behavioral health, and to help inform actions in support of President Trump's vision to Make America Healthy Again [MAHA],' said Substance Abuse and Mental Health Services Administration (SAMHSA) Principal Deputy Assistant Secretary Art Kleinschmidt, PhD, MBA, LPC, LAC, in the news release. The report was published online on July 28. Marijuana, Hallucinogen Use Rising Among substances included in the survey, alcohol was used most often, with 46.6% reporting usage in the previous month. In 2024, 134.3 million people reported drinking alcohol in the month prior to completing the survey, a decline of 400,000 from 2023. The number of adults binge drinking in the prior month also dropped from 45.6% in 2023 to 43.1% in 2024. Among people aged 12 years or older, 63.7 million people reported past month use of tobacco products or vaped nicotine. Among adolescents aged 12-17 years who reported tobacco or nicotine use, 71.5% consumed nicotine solely by vaping. From 2021 to 2024, marijuana consumption in the overall cohort rose from 19.0% to 22.3% and hallucinogen use increased by roughly 1%. Over the past year, 1 in 4 Americans reported using an illicit drug, including 4.3 million who used cocaine (0.2% decrease from 2021) and 7.6 million who misused prescription opioids (0.4% decrease from 2021). There was no change in rates of suicidal ideation or attempts among adults overall during the study period. However, the rate of attempts increased by 0.4% among those aged 50 years or older, or an increase of roughly 500,000 people. Attempted suicides among teens decreased from 3.6% to 2.7%. About 1 in 5 people who were identified as needing substance abuse treatment received that treatment in the year prior to the survey. Among the 61.5 million adults with any mental illness, over half received mental health treatment in the past year. The findings come after months of federal budget cuts; earlier this year, an alliance of professional mental health organizations spoke out about the dangers of such losses to SAMSHA. So far, a third of the agency's staff has been cut and $1 billion withdrawn from its operating budget. 'The reality is we are facing unique addiction and mental health challenges in our country…By addressing mental health and addiction head-on we can make real, tangible progress in achieving our MAHA goals and realize a future where individuals, families, and communities are healthy and thriving,' Kleinschmidt said in an accompanying release.
